XML 22 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Preferred Stock
Additional Paid-in Capital
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
Beginning Balances at Dec. 31, 2019 $ 8,290 $ 84   $ 1,229,417 $ (2,387) $ (1,218,824)
Beginning Balances (in shares) at Dec. 31, 2019   83,871 5      
Conversion of preferred stock 1 $ 1        
Conversion of preferred stock, shares   700        
Conversion of preferred stock, shares     (1)      
Issuance of common stock upon exercise of stock options and restricted stock awards, net 13 $ 1   12    
Issuance of common upon exercise of stock options and restricted stock awards, net (in shares)   735        
Issuance of common stock under Employee Stock Purchase Plan 311     311    
Issuance of common stock under Employee Stock Purchase Plan (in shares)   91        
Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement 107,696 $ 23   107,673    
Issuance of common stock, net of issuance costs, in conjunction with an At Market Sales Agreement (in shares)   24,106        
Stock compensation expense 5,866     5,866    
Total other comprehensive income (Loss) 292       292  
Net income (loss) (64,174)         (64,174)
Ending Balances at Jun. 30, 2020 58,295 $ 109   1,343,279 (2,095) (1,282,998)
Ending Balances (in shares) at Jun. 30, 2020   109,503 4      
Beginning Balances at Mar. 31, 2020 11,824 $ 88   1,245,730 (2,575) (1,231,419)
Beginning Balances (in shares) at Mar. 31, 2020   87,599 5      
Conversion of preferred stock 1 $ 1        
Conversion of preferred stock, shares   700        
Conversion of preferred stock, shares     (1)      
Issuance of common stock upon exercise of stock options and restricted stock awards, net 14     14    
Issuance of common upon exercise of stock options and restricted stock awards, net (in shares)   7        
Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement 93,467 $ 20   93,447    
Issuance of common stock, net of issuance costs, in conjunction with an At Market Sales Agreement (in shares)   21,197        
Stock compensation expense 4,088     4,088    
Total other comprehensive income (Loss) 480       480  
Net income (loss) (51,579)         (51,579)
Ending Balances at Jun. 30, 2020 58,295 $ 109   1,343,279 (2,095) (1,282,998)
Ending Balances (in shares) at Jun. 30, 2020   109,503 4      
Beginning Balances at Dec. 31, 2020 58,693 $ 110   1,352,374 273 (1,294,064)
Beginning Balances (in shares) at Dec. 31, 2020   110,190 4      
Exercise of warrants 7,928 $ 1   7,927    
Exercise of warrants, shares   750        
Issuance of common stock upon exercise of stock options and restricted stock awards, net 1,335     1,335    
Issuance of common upon exercise of stock options and restricted stock awards, net (in shares)   833        
Issuance of common stock under Employee Stock Purchase Plan 383     383    
Issuance of common stock under Employee Stock Purchase Plan (in shares)   104        
Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement 28,156 $ 3   28,153    
Issuance of common stock, net of issuance costs, in conjunction with an At Market Sales Agreement (in shares)   2,879        
Purchase of capped call options related to issuance of Convertible Notes (27,240)     (27,240)    
Stock compensation expense 9,747     9,747    
Total other comprehensive income (Loss) (986)       (986)  
Net income (loss) 5,364         5,364
Ending Balances at Jun. 30, 2021 83,380 $ 114   1,372,679 (713) (1,288,700)
Ending Balances (in shares) at Jun. 30, 2021   114,756 4      
Beginning Balances at Mar. 31, 2021 99,762 $ 114   1,393,947 (1,126) (1,293,173)
Beginning Balances (in shares) at Mar. 31, 2021   114,563 4      
Issuance of common stock upon exercise of stock options and restricted stock awards, net 948     948    
Issuance of common upon exercise of stock options and restricted stock awards, net (in shares)   193        
Purchase of capped call options related to issuance of Convertible Notes (27,240)     (27,240)    
Stock compensation expense 5,024     5,024    
Total other comprehensive income (Loss) 413       413  
Net income (loss) 4,473         4,473
Ending Balances at Jun. 30, 2021 $ 83,380 $ 114   $ 1,372,679 $ (713) $ (1,288,700)
Ending Balances (in shares) at Jun. 30, 2021   114,756 4